BlossomHill Therapeutics, Inc.
BLSM - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$399.87M
Close$
$3.93
71.4% downside
Current Fair Value
71.4% downsideOvervalued by 71.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $399.87 Million |
|---|---|
| Enterprise Value | $327.86 Million |
| Earnings per Share | $-2.08 |
| Beta | 0 |
| Outstanding Shares | 27,136,960 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -1.45 |
|---|---|
| PEG | -1.15 |
| Price to Sales | - |
| Price to Book Ratio | 4.58 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.28 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 18, 2026
EPS Estimate
$-0.93
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
December 18, 2026
EPS Estimate
$-0.93
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About BlossomHill Therapeutics, Inc.
69 employees
CEO: Jing Rong Jean Cui
Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.